Analysis & ranking
PHASE 2 — Evidence and Impact Analysis
Article 1 — Myhre et al. (2026) — Long-term HIV-1 remission via CCR5Δ32/Δ32 HSCT
PMID: 41975092 | Nature Microbiology | Triage Score: 8
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | Adds a confirmed new case to an extremely small series (now ~6 globally). Sibling donor CCR5Δ32/Δ32 route with prospective follow-up in Nature Microbiology is materially additive to the field — not paradigm-shifting alone, but meaningfully consolidates proof of mechanism. |
| Clinical Relevance | 6 | Directly demonstrates HIV functional cure is achievable, but is gated by a confluence of rare conditions (concurrent hematologic malignancy requiring HSCT + availability of CCR5Δ32/Δ32 sibling). Not broadly applicable to the ~38 million people living with HIV. |
| Population Reach | 4 | Directly applicable to a vanishingly small sub-population; broader relevance lies in validating the CCR5-knockout gene therapy pathway that could eventually scale. |
| Implementation Speed | 3 | CCR5Δ32/Δ32 matched sibling donors are exceedingly rare (~1% homozygous frequency in Northern European populations). Gene-edited HSCT mimics are in early trials but years from routine use. |
| Evidence Strength | 5 | Single patient, prospective longitudinal — the gold standard for this type of report, but n=1 by definition. Strong mechanistic basis. Publication in Nature Microbiology signals rigorous peer review. |
Key quantitative result: Long-term HIV-1 remission (duration not extractable from abstract alone); consistent with prior cases (Berlin: 20+ yrs, London: 5+ yrs, Düsseldorf, City of Hope, Geneva).
External validation: Part of a now ~6-case series using the same biological mechanism — each new case constitutes independent biological replication of the mechanism, even if not a formal clinical trial.
Main limitation: n=1; patient had concurrent hematologic malignancy necessitating HSCT, making this approach inapplicable as a standalone HIV cure strategy for the general HIV population.
Equity implications: CCR5Δ32/Δ32 mutation is enriched in Northern European ancestry populations. Patients of African, Asian, or Latino descent — who bear a disproportionate share of the global HIV burden — are at lower probability of having a compatible donor and are systematically underserved by this specific approach.
Evidence Maturity: Validated ✓ (confirmed; consistent with Phase 1 classification — validates mechanism across multiple independent cases)
Article 2 — Lammers et al. (2026) — Survivorship care in Hodgkin lymphoma survivors
PMID: 41975247 | JNCI | Triage Score: 7
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Survivorship care as a concept is well established; the novelty lies in the quantification of burden reduction in a well-characterized Dutch cohort with robust follow-up infrastructure. |
| Clinical Relevance | 7 | Directly actionable — structured survivorship pathways are implementable at oncology centers. Hodgkin lymphoma survivors face substantial late effects (cardiac, pulmonary, secondary malignancies). |
| Population Reach | 5 | Hodgkin lymphoma has high cure rates (~85–90%), producing a large survivor population with multi-decade late-effect risk. Netherlands-specific but generalizable. |
| Implementation Speed | 7 | Survivorship care programs exist and can be scaled; findings directly support guideline integration and resource allocation decisions. |
| Evidence Strength | 6 | Multi-center observational cohort; well-suited design for survivorship questions but cannot establish causality. JNCI publication standard. Sample size not extractable from abstract. |
Key quantitative result: Not extractable from abstract — reduction in "burden of disease" reported but magnitude unclear.
External validation: Builds on the established Dutch Hodgkin lymphoma survivorship infrastructure (BETER consortium); prior studies validate the late-effects framework.
Main limitation: Observational design — self-selection into survivorship care programs may confound outcomes. Abstract-only access limits full assessment.
Equity implications: Dutch healthcare system provides near-universal access; findings may not translate to settings with fragmented survivorship infrastructure (e.g., low-resource settings, uninsured populations in the US).
Evidence Maturity: Validated ✓
Article 3 — Eisenhauer et al. (2026) — KLK7/KLK10/DSG3 in early pancreatic lesions
PMID: 41974993 | Scientific Reports | Triage Score: 7
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | KLK7 and KLK10 have not been prominently featured as pancreatic early detection biomarkers; their co-upregulation with DSG3 in early lesions is a genuinely novel observation. |
| Clinical Relevance | 4 | Early detection of pancreatic cancer is a massive unmet need, but this is tissue-based (not blood/urine); transition to a deployable test requires substantial further development. Capped per exploratory maturity. |
| Population Reach | 7 | Pancreatic cancer kills ~50,000 Americans annually with <12% 5-year survival; any early detection advance addresses a high-burden, high-mortality disease. |
| Implementation Speed | 2 | Tissue biomarker study — requires validation in independent cohorts, then translation to accessible sampling (ideally liquid biopsy). Years from clinical use. |
| Evidence Strength | 4 | Translational tissue analysis; design quality limited by unclear sample size and single-institution character. Classification confidence medium. Scientific Reports is peer-reviewed but not a high-selectivity venue. |
Key quantitative result: Upregulation of KLK7, KLK10, DSG3 — fold-change or statistical metrics not available from abstract.
External validation: No external validation at this stage. Exploratory, single-site study.
Main limitation: Tissue-based, not translatable to minimally invasive screening without further mechanistic work. No specificity data versus benign pancreatic lesions reported in abstract.
Equity implications: Pancreatic cancer disproportionately affects African Americans and lower-income populations with late presentation. Early detection tools, if developed, would be most impactful in these underserved groups — but access to endoscopic surveillance programs remains inequitable.
Evidence Maturity: Exploratory ✓
Article 4 — Wang et al. (2026) — Enzymatic cascade urinary cancer diagnostics
PMID: 41973904 | ACS Nano | Triage Score: 7
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | Enzymatic cascade amplification for visual, equipment-free urinary cancer detection is a genuinely creative engineering approach. ACS Nano-level innovation. |
| Clinical Relevance | 3 | Capped per non-human/preclinical study rule and unknown species model. No clinical validation data available. Concept is compelling but proof-of-concept only. |
| Population Reach | 6 | If validated, a non-invasive, low-cost urine test could reach populations globally, including low-resource settings where current diagnostics are unavailable. |
| Implementation Speed | 2 | Lab-stage; requires cancer type specificity validation, clinical sensitivity/specificity studies, regulatory approval. Likely 7–10+ years from clinical deployment. |
| Evidence Strength | 3 | Proof-of-concept assay development — no clinical samples confirmed. Species unknown. Medium classification confidence. |
Key quantitative result: Not available from abstract (sensitivity/specificity data not reported).
External validation: None at this stage.
Main limitation: Unknown species/model, no clinical samples, cancer type specificity unclear. The "visual" detection claim requires colorimetric validation across real biological matrices.
Equity implications: Non-invasive urine tests have intrinsically favorable equity profiles if cost is controlled. Potentially accessible in settings without laboratory infrastructure.
Evidence Maturity: Exploratory ✓
Article 5 — Chen et al. (2026) — Multimodal omics of NSCLC lymph node metastasis
PMID: 41975179 | Nature Communications | Triage Score: 7
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Multimodal omics integration (genomic/transcriptomic/proteomic) applied specifically to lymph node metastasis origin factors in NSCLC is an original and technically sophisticated approach. |
| Clinical Relevance | 5 | Identifies therapeutic targets and prognostic markers — but these require prospective validation and therapeutic translation. Not immediately practice-changing. |
| Population Reach | 7 | NSCLC is the leading cause of cancer death globally; lymph node metastasis is a critical staging and prognostic factor affecting treatment decisions for hundreds of thousands annually. |
| Implementation Speed | 3 | Exploratory omics — targets identified need drug development, clinical trial validation. 5–10 year horizon for any derived interventions. |
| Evidence Strength | 6 | Nature Communications quality; integrative multimodal design is rigorous. Sample size not reported. Exploratory maturity. High classification confidence. |
Key quantitative result: Not extractable from abstract.
External validation: Not explicitly described. Exploratory study.
Main limitation: Exploratory — mechanistic insights require prospective validation. Functional significance of identified drivers unproven in independent clinical datasets.
Equity implications: NSCLC disproportionately affects lower-income populations and certain ethnic groups with higher smoking prevalence. Precision targets derived here may only be actionable in well-resourced genomic medicine contexts.
Evidence Maturity: Exploratory ✓
Article 6 — Zong et al. (2026) — HERV-K102 targeting elicits pyroptosis in AML
PMID: 41975153 | Blood Research | Triage Score: 5
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 9 | Targeting endogenous retroviral elements (HERVs) to trigger pyroptosis in cancer cells is a highly original concept — leveraging the tumor's own "viral fossil" as an immune vulnerability is conceptually groundbreaking. |
| Clinical Relevance | 4 | Capped at 4 for preclinical (non-human) study. If mechanism translates, AML is a disease of very high unmet need with limited durable cure options. |
| Population Reach | 5 | AML affects ~20,000 new patients annually in the US with poor outcomes in older adults; globally significant. Relative to the rare disease context, this is a moderately sized but highly under-served population. |
| Implementation Speed | 2 | Preclinical mechanistic study. Target validation in human AML models, then IND-enabling studies, then Phase 1 trials — realistically 7–12 years from clinical availability. |
| Evidence Strength | 4 | Preclinical mechanistic (mixed in vitro/animal); capped per non-human rule. Blood Research is a reputable but mid-tier hematology journal. Abstract only. |
Key quantitative result: Pyroptotic cell death in AML cells confirmed — quantitative metrics (IC50, cell death %, in vivo tumor reduction) not available from abstract.
External validation: None. First-in-class mechanistic report.
Main limitation: Preclinical only; species-to-human translation of HERV-K expression patterns is uncertain. Specificity for AML vs. normal hematopoietic cells critical and unknown.
Equity implications: AML disproportionately affects older adults; any new therapeutic target is relevant to this high-mortality population regardless of equity context.
Evidence Maturity: Revised to Exploratory (mechanism validated preclinically; far from clinical translation despite conceptual strength)
Article 7 — Podvin et al. (2026) — CTCs in Multiple Myeloma (Review)
PMID: 41974595 | American Journal of Hematology | Triage Score: 5
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | CTCs in myeloma is an established field; this is a synthesis by leading investigators (Ghobrial, Paiva) that likely advances the conceptual framework but introduces no new data. |
| Clinical Relevance | 5 | Synthesizes a body of evidence relevant to monitoring strategies; potentially useful for clinical decision-making on biopsy frequency and disease assessment. |
| Population Reach | 5 | Multiple myeloma affects ~35,000 new patients/year in the US. CTC monitoring could reduce need for invasive bone marrow biopsies. |
| Implementation Speed | 4 | CTC technology is available but not yet standardized for routine myeloma monitoring; guideline adoption would require additional prospective evidence. |
| Evidence Strength | 4 | Narrative review — no new data. High-quality authors and journal. |
Evidence Maturity: Validated ✓ (field-level synthesis)
Article 8 — Assadi et al. (2026) — Precision oncology in meningioma (Review)
PMID: 41975017 | Nature Reviews Clinical Oncology | Triage Score: 6
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Meningioma precision oncology is an emerging but increasingly populated field; WHO 2021 molecular grading has shifted practice. This review synthesizes the state-of-the-art at a high-impact venue. |
| Clinical Relevance | 6 | Directly addresses an underserved CNS tumor with limited systemic therapy options; Nature Rev Clin Oncol reviews influence practice patterns and guideline development. |
| Population Reach | 5 | Meningiomas are the most common primary brain tumor (~40% of all CNS tumors); recurrent/high-grade disease represents a serious unmet need. |
| Implementation Speed | 5 | Molecular subtyping tools (WHO 2021) are already available; targeted agents in trials. Review may accelerate clinical uptake of available tools. |
| Evidence Strength | 5 | Expert consensus review; no new data but high-quality synthesis. Nature Rev Clin Oncol is a top-tier venue. |
Evidence Maturity: Validated ✓
Article 9 — Guan et al. (2026) — Cas12f ortholog genome editing efficiency
PMID: 41975095 | Nature Structural & Molecular Biology | Triage Score: 5
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Mechanistic delineation of Cas12f ortholog efficiency differences is genuinely useful for the gene therapy field; miniaturized CRISPR systems are actively sought for AAV delivery. |
| Clinical Relevance | 2 | In vitro mechanistic; no clinical samples. Indirect relevance through gene therapy tool development. |
| Population Reach | 5 | If optimized Cas12f variants accelerate gene therapies, reach could be very broad across multiple genetic diseases. |
| Implementation Speed | 2 | Toolbox science — years of development before any Cas12f-based therapeutic reaches patients. |
| Evidence Strength | 6 | Rigorous structural/biochemical study, Nature Struct Mol Biol quality, but in vitro only. |
Evidence Maturity: Exploratory ✓
Article 10 — Herr et al. (2026) — G-quadruplex replication stress and rare diseases (Review)
PMID: 41975004 | Communications Biology | Triage Score: 6
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Unifying multiple rare diseases under the G-quadruplex replication stress framework is a conceptually valuable synthesis; not entirely novel but meaningfully integrative. |
| Clinical Relevance | 4 | Mechanistic/therapeutic implications are indirect; no approved drugs targeting G-quadruplex resolution yet. |
| Population Reach | 4 | Rare disease populations (Fanconi anemia, Bloom syndrome) are small individually; unifying framework could enable shared drug development across conditions. |
| Implementation Speed | 3 | Drug development targeting G-quadruplex helicases is early-stage. |
| Evidence Strength | 5 | Systematic review/synthesis; no new experimental data. Communications Biology is a reputable mid-tier venue. |
Evidence Maturity: Exploratory ✓ (revised from Validated — mechanistic synthesis without clinical validation data)
Article 11 — Masuzawa et al. (2026) — Renal lesions in TAFRO and POEMS syndromes
PMID: 41975025 | Clinical and Experimental Nephrology | Triage Score: 6
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Morphological renal characterization in TAFRO/POEMS via multicenter cohort is meaningful in an ultra-rare disease with sparse literature. Diagnostic pattern description is original in this context. |
| Clinical Relevance | 6 | Directly aids pathologists and nephrologists in diagnosing these ultra-rare conditions; Population Reach adjustment per rare disease scoring rule (unmet need is high relative to disease population). |
| Population Reach | 3 | Ultra-rare (TAFRO: <300 cases worldwide); judged relative to the relevant clinical population — for those patients, diagnostic guidance is highly impactful. |
| Implementation Speed | 6 | Morphological criteria can be directly applied to renal biopsy interpretation — no regulatory pathway required; near-term implementable for specialists. |
| Evidence Strength | 6 | Retrospective multicenter Japanese cohort — appropriate design for rare disease characterization. Limitations: retrospective, Japan-specific. |
Evidence Maturity: Exploratory → conditionally Validated within its rare-disease context (multicenter morphological consensus)
Article 12 — Wu et al. (2026) — SR-BI and HFpEF T-cell cardiotropism
PMID: 41975084 | EMBO Molecular Medicine | Triage Score: 5
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | Identifying SR-BI as an endothelial gatekeeper against T-cell cardiac infiltration in HFpEF is a genuinely novel mechanistic finding. Opens a new immune-endothelial therapeutic axis. |
| Clinical Relevance | 4 | Capped per animal model rule. HFpEF affects ~50% of all heart failure patients with essentially no disease-modifying therapies — translational potential is very high if mechanism holds in humans. |
| Population Reach | 8 | HFpEF affects an estimated 3–4 million Americans; globally one of the largest unmet therapeutic needs in cardiology. |
| Implementation Speed | 2 | Animal model; needs human validation, druggability assessment, IND studies. 8–12+ year horizon. |
| Evidence Strength | 4 | Preclinical animal model only; capped per non-human rule. EMBO Mol Med is a high-quality journal. |
Evidence Maturity: Exploratory ✓
Article 13 — Kuwagata et al. (2026) — SGLT2i eGFR slope vs. proteinuria in CKD
PMID: 41975024 | Clinical and Experimental Nephrology | Triage Score: 5
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Mechanistically interesting — decoupling eGFR benefit from proteinuria effect challenges a common assumption about SGLT2i nephroprotection. |
| Clinical Relevance | 5 | Relevant to nephrologists managing SGLT2i therapy; may inform clinical monitoring strategies and mechanistic understanding. |
| Population Reach | 6 | CKD affects ~37 million Americans; SGLT2i are now widely used. Any mechanistic insight into their nephroprotective action has broad relevance. |
| Implementation Speed | 4 | Real-world data, but single-center and Japanese population only; requires replication before practice impact. |
| Evidence Strength | 4 | Retrospective single-center real-world analysis — significant confounding risk, limited generalizability. |
Evidence Maturity: Exploratory ✓
Article 14 — Zhang & Gems (2026) — C. elegans longevity and decrepitude
PMID: 41974728 | Nature Communications | Triage Score: 5
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 9 | Reframing longevity interventions as "expanded decrepitude" rather than decelerated aging is conceptually provocative and potentially field-reshaping for aging research. Nature Commun quality. |
| Clinical Relevance | 2 | C. elegans model — capped per non-human rule. Indirect conceptual relevance to human longevity research interpretation. |
| Population Reach | 3 | No direct patient population; indirect relevance to the aging research and longevity therapeutics field. |
| Implementation Speed | 1 | Conceptual reframing — does not provide a clinical intervention. Impact is methodological and interpretive. |
| Evidence Strength | 6 | Rigorous model organism mortality kinetics analysis, Nature Communications peer review. Limitation: C. elegans biology differs substantially from human aging. |
Evidence Maturity: Exploratory ✓
Articles 15–20 — Abbreviated Scoring
| # | PMID | Title (short) | Novelty | Clin Rel | Pop Reach | Impl Speed | Evid Strength | Notes |
|---|---|---|---|---|---|---|---|---|
| 15 | 41975140 | Borderline resectable NSCLC review | 3 | 5 | 6 | 4 | 4 | Narrative review, no new data; clinically useful synthesis |
| 16 | 41975002 | TNF targets in older AML (Letter) | 4 | 3 | 4 | 2 | 2 | Letter, no abstract; low confidence. Excluded pipeline |
| 17 | 41975071 | Alt vs matched donor AML AYA (Letter) | 3 | 4 | 4 | 3 | 2 | Letter, no abstract; excluded pipeline |
| 18 | 41975104 | EBV+ CD8+ PTCL post-transplant | 4 | 3 | 2 | 2 | 2 | Single case report; rare entity |
| 19 | 41974652 | AI cell culture analytics | 4 | 2 | 2 | 3 | 5 | Lab methods paper; no clinical relevance |
| 20 | 41975193 | Yttrium oxide NPs in HeLa cells | 3 | 1 | 2 | 1 | 2 | In vitro only; title-only classification; low confidence |
PHASE 3 — Ranking
Conflict Check
No direct conflicts between articles in this batch. Articles 3 and 4 are complementary (early cancer detection from different modalities). Article 13 (SGLT2i) is consistent with but adds nuance to the established literature on SGLT2i nephroprotection; no contradictory findings within this batch.
Composite Impact Score Calculation
Weights: Clinical Relevance 30% | Population Reach 25% | Scientific Novelty 20% | Implementation Speed 15% | Evidence Strength 10%
| Rank | Article | PMID | Flag | CR | PR | SN | IS | ES | Impact Score | Triage Score |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Hodgkin lymphoma survivorship care | 41975247 | 🟢 | 7 | 5 | 5 | 7 | 6 | 6.10 | 7 |
| 2 | HIV-1 remission via CCR5Δ32/Δ32 HSCT | 41975092 | 🟠 | 6 | 4 | 8 | 3 | 5 | 5.45 | 8 |
| 3 | NSCLC LN metastasis multimodal omics | 41975179 | ⚪ | 5 | 7 | 7 | 3 | 6 | 5.65 | 7 |
| 4 | KLK7/KLK10/DSG3 pancreatic early detection | 41974993 | 🔴 | 4 | 7 | 7 | 2 | 4 | 5.05 | 7 |
| 5 | Meningioma precision oncology (Review) | 41975017 | ⬜ | 6 | 5 | 5 | 5 | 5 | 5.35 | 6 |
| 6 | SR-BI and HFpEF T-cell cardiotropism | 41975084 | ⚪ | 4 | 8 | 8 | 2 | 4 | 5.20 | 5 |
| 7 | TAFRO/POEMS renal morphology | 41975025 | 🟡 | 6 | 3 | 6 | 6 | 6 | 5.25 | 6 |
| 8 | Urinary enzymatic cascade diagnostics | 41973904 | 🔴 | 3 | 6 | 8 | 2 | 3 | 4.45 | 7 |
| 9 | SGLT2i eGFR vs proteinuria in CKD | 41975024 | ⬜ | 5 | 6 | 5 | 4 | 4 | 5.00 | 5 |
| 10 | HERV-K102 / AML pyroptosis | 41975153 | ⚪ | 4 | 5 | 9 | 2 | 4 | 4.75 | 5 |
| 11 | G-quadruplex rare disease review | 41975004 | 🟡 | 4 | 4 | 6 | 3 | 5 | 4.35 | 6 |
| 12 | CTCs in multiple myeloma (Review) | 41974595 | ⬜ | 5 | 5 | 4 | 4 | 4 | 4.60 | 5 |
| 13 | Cas12f ortholog CRISPR efficiency | 41975095 | ⚪ | 2 | 5 | 7 | 2 | 6 | 3.90 | 5 |
| 14 | C. elegans longevity / decrepitude | 41974728 | ⚪ | 2 | 3 | 9 | 1 | 6 | 3.65 | 5 |
| 15 | Borderline resectable NSCLC review | 41975140 | ⬜ | 5 | 6 | 3 | 4 | 4 | 4.65 | 5 |
Articles 16–20 are excluded from the main ranking per pipeline rules (Letters without abstracts, single case report, lab-only, title-only).
Ranked Summary Table
| Rank | Article | Flag | Impact Score | Triage Score | Study Design | Evidence Maturity |
|---|---|---|---|---|---|---|
| 🥇 1 | Hodgkin lymphoma survivorship care — Lammers et al. | 🟢 | 6.10 | 7 | Multi-center observational cohort | Validated |
| 2 | NSCLC LN metastasis omics — Chen et al. | ⚪ | 5.65 | 7 | Multimodal omics profiling | Exploratory |
| 3 | HIV-1 remission CCR5Δ32/Δ32 — Myhre et al. | 🟠 | 5.45 | 8 | Clinical case report w/ prospective follow-up | Validated |
| 4 | Meningioma precision oncology — Assadi et al. | ⬜ | 5.35 | 6 | Expert consensus review | Validated |
| 5 | SR-BI / HFpEF — Wu et al. | ⚪ | 5.20 | 5 | Preclinical animal model | Exploratory |
| 6 | TAFRO/POEMS renal morphology — Masuzawa et al. | 🟡 | 5.25 | 6 | Retrospective multicenter | Exploratory |
| 7 | KLK7/KLK10/DSG3 pancreatic — Eisenhauer et al. | 🔴 | 5.05 | 7 | Translational biomarker study | Exploratory |
| 8 | SGLT2i eGFR vs proteinuria — Kuwagata et al. | ⬜ | 5.00 | 5 | Retrospective real-world | Exploratory |
| 9 | HERV-K102 / AML pyroptosis — Zong et al. | ⚪ | 4.75 | 5 | Preclinical mechanistic | Exploratory |
| 10 | Borderline resectable NSCLC — Mielgo-Rubio et al. | ⬜ | 4.65 | 5 | Narrative review | Validated |
| 11 | CTCs in myeloma — Podvin et al. | ⬜ | 4.60 | 5 | Narrative review | Validated |
| 12 | Urinary cascade diagnostics — Wang et al. | 🔴 | 4.45 | 7 | Proof-of-concept assay | Exploratory |
| 13 | G-quadruplex rare diseases — Herr et al. | 🟡 | 4.35 | 6 | Systematic/mechanistic review | Exploratory |
| 14 | Cas12f CRISPR orthologs — Guan et al. | ⚪ | 3.90 | 5 | Structural/biochemical | Exploratory |
| 15 | C. elegans longevity — Zhang & Gems | ⚪ | 3.65 | 5 | Model organism longitudinal | Exploratory |
Rank 1 Justification
Lammers et al. ranks first because it is the article in this batch most likely to directly change patient care in the near term without additional development steps. Hodgkin lymphoma survivors number in the hundreds of thousands globally, bearing a heavy burden of late treatment effects — cardiac disease, pulmonary toxicity, secondary malignancies — for decades after cure. A multi-center Dutch cohort showing that structured survivorship care meaningfully reduces this disease burden, published in JNCI, provides immediately actionable evidence that oncology programs can use to justify building or expanding survivorship pathways. The implementation barrier is organizational rather than regulatory or scientific, making near-term uptake genuinely feasible. While the Myhre HIV cure paper (Article 1) captured the highest OpenClaw triage score (8) on the strength of its conceptual novelty, its n=1 design, extreme rarity of the required donor type, and dependence on concurrent hematologic malignancy substantially constrain its composite impact score under the Phase 3 weighting rubric, which emphasizes clinical reach and implementation speed.
Why it matters: Hundreds of thousands of Hodgkin lymphoma survivors are cured of their cancer but carry a lifelong elevated risk of serious late effects — and this study provides multi-center evidence that structured follow-up can measurably reduce that burden. Every cancer center that treats Hodgkin lymphoma should be reading this.
Note on Article 2 (HIV cure) vs. Article 1 ranking: The triage agent correctly flagged PMID 41975092 as the standout HIGH find of the day on novelty and unmet need — and for a scientific audience or HIV specialist readership, it may warrant #1 attention. The Phase 3 composite score places it at #3 because the weighting heavily penalizes the combination of n=1 evidence strength and very low implementation speed. Both framings are defensible depending on your audience.